DarioHealth (DRIO) Q3 2026 earnings review
DarioHealth hardware sales jump, but its core software revenue shrinks
DarioHealth, which sells connected health devices and chronic-care software, grew total sales on consumer hardware while its enterprise software business shrank. Total revenue rose 6% from a year ago as direct-to-consumer sales jumped 48%, and research cuts narrowed the operating loss by 15%. Chief executive Erez Raphael said the enterprise model is working, yet services revenue fell 20% on lost legacy contracts.
| Revenue | $5.3M +6% from a year ago |
|---|---|
| Services revenue | $2.6M -20% from a year ago |
| Contracted and late-stage ARR | $13.1M unchanged from last quarter |
| Revenue outlook | Unchanged faster growth late 2026 into 2027 |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because the core enterprise turnaround still shows up in press releases rather than the income statement. Channel partners brought in a major New Jersey insurer and a GLP-1 weight-loss drug delivery project, and July's stock sale lifted cash to $31 million. The bad news: the pool of signed and late-stage recurring contracts stayed stuck at $13.1 million for a second quarter, and share count nearly quadrupled from a year ago.
The question now is whether the $13.1 million contract pool will finally lift quarterly services revenue or keep sliding into future years as older deals expire. If signed accounts activate on schedule, services sales will turn upward; if employer rollouts drag, hardware will keep carrying the business while cash burn continues. Fourth-quarter services revenue and January onboarding numbers will tell.
🐂 Bull Case
Direct-to-Consumer Hardware Carries the Top Line
DarioHealth sells connected medical devices directly to consumers alongside its software for employers and insurers. Total sales rose 6.1% from a year ago to $5.3 million, breaking a multi-quarter decline. Direct-to-consumer sales drove the turn, rising about 48% from a year ago.
Consumer hardware revenue climbed 53.3% from a year ago and 6.4% from last quarter to $2.8 million. By our math, hardware now brings in 51.9% of total revenue, up from 35.9% a year ago, keeping overall sales growing while the enterprise side lags.
What to watch: consumer hardware sales in the fourth quarter. Another sequential gain would show that direct consumer demand can support the top line while enterprise contracts ramp.
Channel Partners Add Health Plans and GLP-1 Scope
DarioHealth relies on reseller partners like Amwell to reach large insurers and on new clinical services to sell more to existing clients. Channel-sourced business more than doubled from a year ago, the company said, and it signed one of New Jersey's largest health plans, covering 1.5 million people, with revenue starting in 2027.
The company also launched Dario Women, for menopause, and Dario Sleep, for sleep apnea, expanding a grocery retailer's contract for 2027. An existing national insurer client is working with the firm to "extend the relationship from the digital program to delivery of the GLP-1 therapy itself", while its DarioIQ artificial intelligence tool lifted early member return rates to 1.7 times the unreached group.
What to watch: fourth-quarter revenue contributions from Dario Women and Dario Sleep. Chief operating officer Lara Dodo previously slated both programs to begin generating sales before year-end.
AI and R&D Cuts Lower the Operating Loss
Finance chief Chen Franco-Yehuda has focused on cutting overhead while the business shifts its model. Operating expenses fell 10.5% from a year ago to $11.2 million, narrowing the GAAP operating loss by 15.2% to $8.0 million. Excluding one-offs such as stock-based pay and amortization, the operating loss held steady from last quarter at $5.3 million, down from $6.0 million a year ago.
- Research and development: 43.2% of revenue, down 23.3 percentage points from a year ago by our math
- General and administrative (overhead): 76.8% of revenue, down 14.4 percentage points from a year ago
- Sales and marketing: 90.6% of revenue, down 1.3 percentage points from a year ago
The company deployed DarioIQ, its generative artificial intelligence software, across internal operations to help trim costs. Sequential GAAP expenses rose 15.7% only because non-cash stock compensation jumped from $0.6 million to $2.2 million.
What to watch: quarterly operating expenses excluding one-offs, now at $8.7 million. Holding this line flat as new health plans launch is necessary to shrink cash burn.
🐻 Bear Case
Signed Recurring Contracts Still Do Not Lift Services
"We believe that our third quarter of 2026 shows that model is working, with multi-condition expansion within existing accounts and new health plan agreements through our channel partners," chief executive Erez Raphael said. DarioHealth wants its business-to-business-to-consumer (B2B2C) model, which sells chronic-care software through employers and insurers, to drive its growth.
The income statement says otherwise. Services revenue, where B2B2C sits, fell 20.4% from a year ago and 1.2% from last quarter to $2.55 million because of the "non-renewal of several of Twill's legacy contracts". Contracted and late-stage annual recurring revenue (ARR), the yearly value of signed and near-signed subscription deals, stayed flat from last quarter at $13.1 million.
This matters because the ARR pool has hovered near $13 million for four quarters without lifting services revenue. Furthermore, about 40% of that pool comes from administrative-services-only health plan deals, where revenue builds over a "multi-year horizon as each employer activates" rather than all at once.
What to watch: fourth-quarter services revenue. If it fails to rise from $2.55 million during the year-end onboarding window, the $13.1 million contract pool is still not converting on schedule.
Share Count Nearly Quadrupled as Cash Burn Continues
DarioHealth ended September with $31.2 million in cash and short-term deposits after raising $22.8 million in net proceeds from a July stock offering, and Franco-Yehuda said the firm has the resources to execute its priorities. That cash sits beside a $31.2 million long-term loan and ongoing operating losses.
- Weighted average common shares: 12.06 million, up 284% from 3.14 million a year ago by our math
- Third-quarter operating cash burn: $5.54 million by our math, after burning $12.11 million in the first half
- Nine-month cash interest paid on long-term loan: $2.93 million, up from $2.26 million a year ago
Because the business still consumes $5.5 million of cash a quarter and must keep $10 million in liquid assets under its loan rules, the July raise leaves roughly four quarters of buffer unless losses shrink much faster.
What to watch: quarterly operating cash burn in the full-year report. Without a drop well below $5 million, the company risks needing another dilutive share sale before reaching breakeven.
Hardware Mix and Fading Refunds Cut Gross Margin
"Our B2B2C gross margin has remained strong, and we are focused on scaling that model," Franco-Yehuda said, noting that B2B2C gross margin excluding one-offs stayed near 80% for an 11th straight quarter. However, total GAAP gross margin slipped to 59.2%, down 1.0 percentage point from a year ago and 2.5 percentage points from last quarter.
Two forces pushed the total margin down. First, a one-time tariff refund under the International Emergency Economic Powers Act shrank from about $0.4 million in the second quarter to about $0.1 million in the third; excluding that refund, gross margin was 57.3% by our math. Second, consumer hardware cost of revenue rose 3.4 percentage points of total revenue from a year ago to 27.3%, outweighing lower software hosting costs.
What to watch: GAAP gross margin once the tariff refunds end. It will stay below 60% until high-margin software services grow faster than consumer device sales.
Risks this quarter didn't answer
Four standing concerns around financial targets, leadership, and corporate strategy received no new figures or updates in the third-quarter release.
- Unquantified revenue ramp and breakeven math: the release gives no dollar outlook for 2026 or 2027, and does not restore the dropped mid-2027 cash-flow breakeven date or the 30% full-year operating-loss reduction target.
- Commercial leadership and loan rules: the release makes no mention of president and chief commercial officer Steven Nelson's medical leave or key-person rules under the credit agreement; the quarterly filing will show any update.
- Strategic review status: the board's special committee review with Perella Weinberg went unmentioned for a second straight quarter; the quarterly filing's subsequent-events note will show if it ended.
- Client-count multi-condition rate and hospital partner: the release reports multi-condition share only as 80% of the ARR pool, not share of new clients, and gives no update on the northeastern hospital network partner.
👓 Other Themes
Third-Party Study Estimates Healthcare Cost Savings
DarioHealth published findings from a third-party review of 17 clinical studies to pitch insurers against rival digital-health tools and general-purpose artificial intelligence. The analysis estimated a 2.5% to 7.2% yearly drop in total healthcare costs, equal to $3.8 million to $10.8 million a year for a 20,000-member plan, and $5,077 in yearly savings per user with type 2 diabetes.
💲 Other KPIs
Deferred revenue — cash customers have paid upfront for services not yet delivered — rose 44.9% from last quarter's $521 thousand, reversing three quarters of sequential declines. Compared with a year ago, the balance is still down 12.2% from $860 thousand, but the quarterly uptick provides a small positive cash inflow.
Working capital tied up in unsold devices and unpaid customer bills shrank again. Inventories fell to $3.54 million from $3.72 million in June and $4.32 million at year-end, while trade receivables dropped to $1.45 million from $1.55 million in June, generating $1.47 million in operating cash over the first nine months.
🔮 Guidance
Unchanged. DarioHealth still expects revenue growth to "accelerate at the end of 2026 and into 2027" as committed recurring contracts and multi-condition expansions convert into recognized sales. However, the healthcare technology firm gave no dollar range, and noted that the newly signed New Jersey health plan and grocery retailer expansion will not contribute revenue until 2027.
Unchanged. Management narrowed its estimate for how much its DarioIQ artificial intelligence system can lift recurring revenue inside existing enterprise accounts to "up to approximately 14% in engagement-based B2B2C ARR from existing customers", right inside last quarter's 10% to 15% band, after measuring higher member re-engagement during the third quarter.
❓ Key Questions
Why is services revenue still falling despite $13.1M in ARR?
Contracted and late-stage recurring revenue has stayed near $13 million for four quarters, yet quarterly services revenue slipped to $2.55 million and 40% of the pool sits in multi-year employer activation deals.
What was B2B2C revenue vs consumer revenue in the third quarter?
The press release reports hardware and services lines, where services fell 20% from a year ago, but leaves the exact B2B2C versus consumer customer split for the quarterly filing.
When does DarioHealth now expect to reach cash-flow breakeven?
The company burned $5.5 million in operating cash this quarter by our math, and has not repeated its old mid-2027 breakeven date or its 30% full-year operating-loss reduction target.
What is the status of the board's strategic review?
DarioHealth hired Perella Weinberg Partners in late 2025 to evaluate inbound interest, but has omitted any mention of the special committee's review for two straight quarters while issuing new stock.